Om

Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing RNA medicines for genetically defined diseases. The company uses its proprietary PRISM platform to design oligonucleotide-based therapies across multiple RNA-targeting approaches, including RNA editing, exon skipping, RNA interference, and antisense silencing. Its current pipeline spans programs in areas such as alpha-1 antitrypsin deficiency, obesity, liver disease, Duchenne muscular dystrophy, and Huntington’s disease, reflecting a focus on both rare and more common disorders. Wave Life Sciences also works through research collaborations that support the discovery and development of nucleic acid therapeutics. Headquartered in Singapore, the company plays a role in the broader genetic medicines market by advancing precision approaches intended to address disease mechanisms at the RNA level.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I WAVE LIFE SCIENCES MED ENDAVU: Køb Wave Life Sciences ($0VS) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Wave Life Sciences, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.